Takeda Pharmaceutical Company Ltd

Takeda Pharmaceutical reports 5% revenue growth in H1 FY24, driven by Growth & Launch portfolio, despite VYVANSE sales decline. The company raises full-year guidance, with core operating profit margin at 30.2%, and focuses on late-stage pipeline investments. Key highlights include ENTYVIO's double-digit growth and Phase 3 trials for TAK-861 and mezagitamab.

Seltorexant, a potent, selective orexin-2 receptor antagonist, improved symptoms of major depressive disorder (MDD) and insomnia in a phase III trial. The study drug, when combined with current antidepressant treatment, showed a significant reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared to placebo. Seltorexant is unique as it targets only OX2 receptors, potentially filling an unmet need for new therapies for MDD and insomnia.

Takeda announced FY2024 H1 results with +13.4% revenue growth at AER and +5.0% at CER, driven by Growth & Launch Products (+18.7% at CER). Core Operating Profit increased +12.9% at CER, with a margin of 30.2%. ENTYVIO® revenue grew double-digits at CER, and geographical expansions included ADZYNMA® in EU and FRUZAQLA® in Japan. A Phase 3 trial for TAK-861 in narcolepsy type 1 started, and an R&D Day is scheduled for December 12 (EST) / 13 (JST). The company upgraded FY2024 forecasts due to stronger-than-expected H1 performance and revised FX assumptions.

PhaseV appoints Hamza Sheikh as Head of Business Development to support global expansion and enhance clinical trial optimization using causal ML.

DelveInsight's 'Epilepsy Pipeline Insight, 2024' report details 75+ companies developing 90+ therapies, including RLS103, CT-010, EQU 001, and others, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Novartis, Pfizer, Sanofi, and Takeda, among others.

Alpha-1 antitrypsin deficiency (AATD) affects 1 in 3,500, causing liver/lung damage. Current treatment, augmentation therapy, doesn't reverse damage. Multiple companies develop candidates to prevent/reverse damage, with RNAi, RNA-editing, and base editing therapies showing promise. Vertex's AATD candidates failed, while Arrowhead, Sanofi, Beam Therapeutics, Wave Life Sciences, and Korro Bio advance their treatments. Augmentation therapy may become obsolete within 5-10 years.

The Orphan Indication Drugs market, focusing on rare diseases, is driven by government support and investment, offering lucrative opportunities for pharmaceutical companies. Key players include Bristol-Myers Squibb, Roche, Novartis, and Johnson & Johnson. The market is segmented by type (biologics, non-biologics) and application (hospital pharmacy, retail pharmacy, online sales), with growth potential in both established and emerging markets.

58 patent attorneys; significant clients include Bitzer Electronics, Electrolux, Johnson Controls, Wago, Cybex, Illinois Tool Works, Mitsubishi Electric, Rockwool, Takeda, Villeroy & Boch; locations in Munich, Bremen, Hamburg, Nuremberg, Düsseldorf, Augsburg, Gera, Hannover, Ludwigshafen, Schorndorf, Osnabrück.

A single dose of CRISPR-based NTLA-2002 reduced angioedema attacks by 75-77% in patients with hereditary angioedema, with 80% of patients in the 50 mg group experiencing complete response.